Demand for chip-design software is booming, making Synopsys the chip-design name to own after Cadence's results. Cadence reported a record $8.2 billion backlog and raised its 2026 revenue-growth outlook to 21%; Synopsys is still about 12% below its May high, and all four models signal Long on Synopsys versus Flat on Cadence. x.com 

Synopsys's investor day directly undercut the bear case, so the tepid stock reaction is hard to explain. It smashed 2027 revenue growth estimates and raised long-term targets for both segments. Its OpenAI partnership to jointly develop a model could look like letting the fox into the henhouse, but it is a direct admission that AI cannot bypass Synopsys's IP-protected data moat, which was the core bear argument. x.com 

Synopsys looks expensive at $415.99, trading at 52 times cash earnings and 42 times next year's, against the roughly 30 times software companies usually get. That puts fair value at about $250.75 to $319.14, so buyers are paying about 30% over fair. The read is valuation levels only, based on reported earnings and revenue estimates, without fundamental work. x.com 

Synopsys's OpenAI deal and investor day have blown up the bear case that frontier AI will disrupt chip-design software. When OpenAI has dominant leverage over a partner, as with Cerebras, it extracts big equity concessions; it did not with Synopsys. KeyBanc called the investor day perfectly executed, citing much better than expected initial FY27 guidance, higher long-term EDA and IP targets, margin expansion and new AWS and OpenAI partnerships, and raised its target while reiterating Overweight. … Show more

Synopsys and Cadence benefit as AI shifts from general-purpose to specific-purpose models, a transition moving unusually fast and a sign this is a continuation of the buildout rather than a new cycle. Synopsys and OpenAI signed a multi-year deal to build GPT-Synopsys, a model that runs Synopsys EDA tools for tasks like timing closure and verification, with shared revenue. Synopsys also announced a multi-year, $1B+ silicon IP agreement with Amazon, showing what EDA players' IP can be used for. … Show more

LLM-driven hardware verification is generally bearish for Synopsys and Cadence, but not predictably enough in the short term to justify betting against them. A post being answered argues verification is the cleanest monetization path for the new LLM capability, with private math pure plays Harmonic and Axiom Math likely to target it, so sentiment on both should worsen. The development is broadly bullish for compute. x.com 

Synopsys and Cadence can turn AI chip design into usage-based revenue, which finally makes AI's impact on EDA quantifiable. Their moat is verified tools only they have, not data. As AI agents run design and verification iterations once buried in engineers' labor costs, EDA can shift from per-seat licenses to billing for compute and tool calls, sold like Claude Code or an API. That could start a loop: AI chip design advances, AI calls EDA more, and EDA usage soars. x.com  x.com  x.com  x.com  x.com  … Show more

Cadence and Synopsys are the shovels of the chip boom, controlling 74% of the EDA software every chip design depends on. Customers essentially never leave: switching is costly and risky, software is half of chip design costs and lifetimes exceed 20 years. Revenue is 80-85% recurring with high-80s gross margins and net margins above 20%, and EDA is projected to grow 12-15% a year as end-product makers such as Tesla join chip firms as clients. x.com 

Synopsys and Cadence face a net competitive negative if large chip designers build custom verification tools in-house, taking share of the largest slice of the EDA workflow. The market will likely sell the incumbents as this gets digested. Offsetting that, faster time to market is becoming table stakes, raising both the value of agentic design tools and the cost of failure. @lokoyacap counters that nothing shows EDA being made unnecessary and that it supports pricier AI-enabled seats. x.com  … Show more

ASML's EUV R&D is starting to pay off through operating leverage. Q3 R&D fell as a share of sales, though one quarter is not a trend. Higher units, IBM sales and EUV/DUV prices put 2028 estimates well above the 2030 guide and ahead of consensus; shares look cheap at €1,530. Assuming 30% prepayment, liabilities imply €42-45bn of orders in 2026's first nine months, subject to invoicing lags. The proposed MATCH Act could restrict China sales; 2029-30 demand is less certain than 2028. x.com  x.com  … Show more